Cocrystal Pharma shares surge 47.06% after-hours after FDA grants Fast Track to CDI-988 for norovirus treatment and prevention.

Cocrystal Pharma surged 47.06% in after-hours trading following the U.S. Food and Drug Administration’s granting of Fast Track designation to its oral protease inhibitor CDI-988, the first oral antiviral candidate for the treatment and prevention of norovirus infection. The designation accelerates regulatory review and allows for more frequent FDA interactions, rolling NDA submissions, and potential Priority Review. CDI-988 targets a conserved 3CL protease region and is currently being evaluated in a Phase 1b challenge study at Emory University. The milestone is seen as a validation of Cocrystal’s structure-based drug discovery platform and its potential to deliver a novel antiviral therapy for a disease with significant global health and economic impact.